Pharmasset Announces Final SVR Data From PROTON Trial With PSI-7977 In Subjects Infected With Hepatitis C Infection Genotype 2 Or 3
Links shared publicly online about this topic.
- 126total visits
Pharmasset Announces Final SVR Data From PROTON Trial With PSI-7977 In Subjects Infected With Hepatitis C Infection Genotype 2 Or 3
Pharmasset, Inc. (Nasdaq: VRUS) announced the final sustained virologic response (SVR) results from its phase 2b PROTON study with PSI-7977 dosed once daily in combination with peginterferon alfa
View full resource at medicalnewstoday.com
Tags: Liver Condition, Hepatitis, Hepatitis C, Infection
Most Recently Shared on July 23, 2011 at 11:05 am By:
Pharmasset Announces Final SVR Data From PROTON Trial With PSI-7977 In Subjects Infected With Hepatitis C Infection Ge... http://mnt.to/3Yvk
Also Shared By:
Advertisement
MNT Liver Disease
@mnt_liver
Pharmasset Announces Final SVR Data From PROTON Trial With PSI-7977 In Subjects Infected With Hepatitis C Infection Ge... http://mnt.to/3Yvk
1 year ago...